
Jill Bargonetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8469973/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A Single Nucleotide Polymorphism in the MDM2 Promoter Attenuates the p53 Tumor Suppressor Pathway and Accelerates Tumor Formation in Humans. Cell, 2004, 119, 591-602.	28.9	1,158
2	Mutant p53 Disrupts Mammary Tissue Architecture via the Mevalonate Pathway. Cell, 2012, 148, 244-258.	28.9	736
3	Wild-type p53 activates transcription in vitro. Nature, 1992, 358, 83-86.	27.8	615
4	Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell, 1991, 65, 1083-1091.	28.9	404
5	Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element Genes and Development, 1992, 6, 1143-1152.	5.9	317
6	Multiple roles of the tumor suppressor p53. Current Opinion in Oncology, 2002, 14, 86-91.	2.4	301
7	The p53 protein is an unusually shaped tetramer that binds directly to DNA Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 3319-3323.	7.1	242
8	Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53 Genes and Development, 1992, 6, 1886-1898.	5.9	220
9	Mutant p53 in MDA-MB-231 breast cancer cells is stabilized by elevated phospholipase D activity and contributes to survival signals generated by phospholipase D. Oncogene, 2006, 25, 7305-7310.	5.9	176
10	Infrared spectroscopy of human tissue. V. Infrared spectroscopic studies of myeloid leukemia (ML-1) cells at different phases of the cell cycle. , 1999, 5, 219-227.		148
11	Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate <i>VEGFR2</i> in breast cancer cells. Genes and Development, 2015, 29, 1298-1315.	5.9	115
12	Dietary downregulation of mutant p53 levels via glucose restriction. Cell Cycle, 2012, 11, 4436-4446.	2.6	111
13	Initiation of rolling-circle replication in pT181 plasmid: initiator protein enhances cruciform extrusion at the origin Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 8560-8564.	7.1	106
14	A Chromatin-associated and Transcriptionally Inactive p53-Mdm2 Complex Occurs in mdm2 SNP309 Homozygous Cells. Journal of Biological Chemistry, 2005, 280, 26776-26787.	3.4	106
15	Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1220-9.	7.1	72
16	A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Research, 2011, 13, R3.	5.0	71
17	Phospholipase D Elevates the Level of MDM2 and Suppresses DNA Damage-Induced Increases in p53. Molecular and Cellular Biology, 2004, 24, 5677-5686.	2.3	64
18	Gain-of-function mutant p53: history and speculation. Journal of Molecular Cell Biology, 2019, 11, 605-609	3.3	59

Jill Bargonetti

#	Article	IF	CITATIONS
19	Inhibition of Human p53 Basal Transcription by Down-regulation of Protein Kinase Cl´. Journal of Biological Chemistry, 2004, 279, 9970-9977.	3.4	57
20	Mutant p53 Forms a Complex with Sp1 on HIV-LTR DNA. Biochemical and Biophysical Research Communications, 2000, 279, 383-390.	2.1	55
21	Differential Activation of p53 by the Various Adducts of Mitomycin C. Journal of Biological Chemistry, 2002, 277, 40513-40519.	3.4	50
22	Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer. Npj Breast Cancer, 2017, 3, .	5.2	50
23	Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Research, 2020, 80, 394-405.	0.9	48
24	Differential Toxicity of DNA Adducts of Mitomycin C. Journal of Nucleic Acids, 2010, 2010, 1-6.	1.2	41
25	Mitomycin–DNA Adducts Induce p53-Dependent and p53-Independent Cell Death Pathways. ACS Chemical Biology, 2007, 2, 399-407.	3.4	34
26	Mouse Double Minute 2 Associates with Chromatin in the Presence of p53 and Is Released to Facilitate Activation of Transcription. Cancer Research, 2006, 66, 3463-3470.	0.9	32
27	Mapping DNA Adducts of Mitomycin C and Decarbamoyl Mitomycin C in Cell Lines Using Liquid Chromatography/Electrospray Tandem Mass Spectrometry. Chemical Research in Toxicology, 2008, 21, 2370-2378.	3.3	32
28	Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells. Breast Cancer Research, 2019, 21, 5.	5.0	30
29	p53 binds to a constitutively nucleosome free region of the mdm2 gene. Oncogene, 1998, 16, 1171-1181.	5.9	28
30	Splicing Up Mdm2 for Cancer Proteome Diversity. Genes and Cancer, 2012, 3, 311-319.	1.9	28
31	Staphylococcus aureus chromosomal mutations that decrease efficiency of Rep utilization in replication of pT181 and related plasmids. Journal of Bacteriology, 1989, 171, 4501-4503.	2.2	24
32	Endogenous Human MDM2-C Is Highly Expressed in Human Cancers and Functions as a p53-Independent Growth Activator. PLoS ONE, 2013, 8, e77643.	2.5	23
33	Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway. Oncotarget, 2017, 8, 47916-47930.	1.8	23
34	DNA Adducts of Decarbamoyl Mitomycin C Efficiently Kill Cells without Wild-Type p53 Resulting from Proteasome-Mediated Degradation of Checkpoint Protein 1. Chemical Research in Toxicology, 2010, 23, 1151-1162.	3.3	19
35	C. elegans CEP-1/p53 and BEC-1 Are Involved in DNA Repair. PLoS ONE, 2014, 9, e88828.	2.5	18
36	Camptothecin and Zeocin Can Increase p53 Levels during All Cell Cycle Stages. Biochemical and Biophysical Research Communications, 2001, 289, 998-1009.	2.1	17

Jill Bargonetti

#	Article	IF	CITATIONS
37	Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient. International Journal of Environmental Research and Public Health, 2016, 13, 22.	2.6	17
38	PARP-Targeted Auger Therapy in p53 Mutant Colon Cancer Xenograft Mouse Models. Molecular Pharmaceutics, 2021, 18, 3418-3428.	4.6	16
39	DNA-binding Properties of the p53 Tumor Suppressor Protein. Cold Spring Harbor Symposia on Quantitative Biology, 1994, 59, 207-213.	1.1	16
40	Splice Variants of MDM2 in Oncogenesis. Sub-Cellular Biochemistry, 2014, 85, 247-261.	2.4	15
41	Functional Consequences of the Interactions of the p53 Tumor Suppressor Protein and SV40 Large Tumor Antigen. Cold Spring Harbor Symposia on Quantitative Biology, 1991, 56, 227-235.	1.1	14
42	Disruption of the p53-Mdm2 complex by Nutlin-3 reveals different cancer cell phenotypes. Ethnicity and Disease, 2008, 18, S2-1-8.	2.3	11
43	Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. Cell Cycle, 2015, 14, 744-754.	2.6	9
44	MDM2, MDM2-C, and mutant p53 expression influence breast cancer survival in a multiethnic population. Breast Cancer Research and Treatment, 2019, 174, 257-269.	2.5	9
45	8-Amino-Adenosine Activates p53-Independent Cell Death of Metastatic Breast Cancers. Molecular Cancer Therapeutics, 2012, 11, 2495-2504.	4.1	8
46	Impedimetric Detection of Mutant p53 Biomarker-Driven Metastatic Breast Cancers under Hyposmotic Pressure. PLoS ONE, 2014, 9, e99351.	2.5	7
47	Targeting Triple Negative Breast Cancer with a Nucleus-Directed p53 Tetramerization Domain Peptide. Molecular Pharmaceutics, 2021, 18, 338-346.	4.6	6
48	<p>MDM2-C Functions as an E3 Ubiquitin Ligase</p> . Cancer Management and Research, 2020, Volume 12, 7715-7724.	1.9	4
49	Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity. Oncotarget, 2021, 12, 1128-1146.	1.8	4
50	Homozygous mdm2 SNP309 cancer cells with compromised transcriptional elongation at p53 target genes are sensitive to induction of p53-independent cell death. Oncotarget, 2015, 6, 34573-34591.	1.8	3
51	Oligomerization of Mutant p53 R273H is not Required for Gain-of-Function Chromatin Associated Activities. Frontiers in Cell and Developmental Biology, 2021, 9, 772315.	3.7	3
52	In Vivo Footprinting and DNA Affinity Chromatography for Analysis of p53 DNA Binding Ability. , 2003, 234, 151-170.		2
53	A Protein in the Yeast Saccharomyces cerevisiae Presents DNA Binding Homology to the p53 Checkpoint Protein and Tumor Suppressor. Biomolecules, 2020, 10, 417.	4.0	2

4

#	Article	IF	CITATIONS
55	Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. Oncotarget, 2019, 10, 5007-5010.	1.8	2
56	How Choreostorming Informs Thinking In Molecular Genetics And Cancer Biology. Leonardo, 0, , 1-8.	0.3	1